Fourth, regulatory pathways for peptides are well-established and continue to evolve to support efficient development while maintaining appropriate safety standards
A patient who begins GLP-1 therapy often experiences significant fatigue, nausea, and reduced appetite in the early weeks
Amongst other GLP-1R agonists, Exenatide uses a combination of mechanisms which may include glucose-dependent stimulation of insulin secretion, suppression of glucagon secretion, enhancement of -cell mass, slowing of gastric emptying, inhibition of food intake, and modulation of glucose trafficking in peripheral tissues (Nielsen, 2004)
Erwin WM, Las Heras F, Islam D, Fehlings MG, Inman RD: The regenerative capacity of the notochordal cell: tissue constructs generated in vitro under hypoxic conditions